13.88
0.43 (3.20%)
| Previous Close | 13.45 |
| Open | 13.11 |
| Volume | 1,264,196 |
| Avg. Volume (3M) | 1,598,638 |
| Market Cap | 1,351,763,200 |
| Price / Book | 2.39 |
| 52 Weeks Range | |
| Earnings Date | 4 May 2026 |
| Diluted EPS (TTM) | -1.88 |
| Total Debt/Equity (MRQ) | 3.97% |
| Current Ratio (MRQ) | 12.00 |
| Operating Cash Flow (TTM) | -115.01 M |
| Levered Free Cash Flow (TTM) | -68.48 M |
| Return on Assets (TTM) | -30.87% |
| Return on Equity (TTM) | -48.45% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Oric Pharmaceuticals, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -3.0 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | -0.10 |
|
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 7.93% |
| % Held by Institutions | 102.70% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Column Group Llc | 31 Dec 2025 | 3,540,777 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 25.00 (HC Wainwright & Co., 80.12%) | Buy |
| 25.00 (Wells Fargo, 80.12%) | Buy | |
| Median | 22.00 (58.50%) | |
| Low | 17.00 (Citigroup, 22.48%) | Buy |
| Average | 21.80 (57.06%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 11.89 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 24 Feb 2026 | 17.00 (22.48%) | Buy | 13.42 |
| HC Wainwright & Co. | 24 Feb 2026 | 25.00 (80.12%) | Buy | 13.42 |
| Wedbush | 24 Feb 2026 | 20.00 (44.09%) | Buy | 13.42 |
| 13 Jan 2026 | 20.00 (44.09%) | Buy | 10.14 | |
| Piper Sandler | 07 Jan 2026 | 22.00 (58.50%) | Buy | 8.68 |
| Wells Fargo | 08 Dec 2025 | 25.00 (80.12%) | Buy | 10.52 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| PISCITELLI DOMINIC | - | 13.42 | -52,000 | -697,840 |
| Aggregate Net Quantity | -52,000 | |||
| Aggregate Net Value ($) | -697,840 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 13.42 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PISCITELLI DOMINIC | Officer | 24 Feb 2026 | Automatic sell (-) | 52,000 | 13.42 | 697,840 |
| PISCITELLI DOMINIC | Officer | 24 Feb 2026 | Option execute | 52,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |